REGENXBIO

REGENXBIO is a clinical-stage biotechnology company. The company's product candidates include: RGX-314, which is being developed for the treatment of wet age-related macular degeneration, a main cause of total and partial vision loss in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-501, which is for the treatment of homozygous familial hypercholesterolemia. The company's gene therapy product candidates deliver genes to cells using adeno-associated virus vectors.
  • TickerRGNX
  • ISINUS75901B1070
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

Regenxbio Inc: 3 directors sold after exercising options/sold

Three Directors at Regenxbio Inc sold after exercising options/sold 96,599 shares at between 50.071USD and 50.307USD. The significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is...

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

Regenxbio Inc: 3 directors sold after exercising options/sold

Three Directors at Regenxbio Inc sold after exercising options/sold 96,599 shares at between 50.071USD and 50.307USD. The significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is...

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

ValuEngine Rating and Forecast Report for RGNX

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• A number of Consumer Cyclical names continue to indicate leadership. (ex. THO, WGO, CROX, WLH, LEN, KBH, PZZA, TXRH, SCVL, GCO, and RH) • The Healthcare Sector has a number of attractive names developing major bases and staging RS reversals. (ex. CAH, HSIC, ITGR, ABT, MLAB, RMD, SYK, MD, RDNT, TRHC, CNC, WCG, RGNX, BEO, and SYNH) • The Technology Sector continues to be long-term leadership. Many issues are extended and we would suggest taking opportunity of any weakness. (ex. TER, AMAT, SYNA, INTC, AVGO, INTU, LPSN, CTXS, ADP, EXLS, PRSP, and FN)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

ResearchPool Subscriptions

Get the most out of your insights

Get in touch